Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ogilvy HealthPR

- PMLiVE

Lilly and Boehringer claim first place for diabetes combination

US FDA backs Glyxambi as first combination of SGLT2 inhibitor and DPP-4 inhibitor.

- PMLiVE

Boehringer and Lilly sway NICE with new Jardiance data

Diabetes drug now backed to help glycaemic control in adults

Novo’s ‘virtual mannequins’ win digital award at PMEA

Med ed programme Decisions in Time was delivered with emotive

- PMLiVE

Integrating digital: developing a social conference

Boehringer Ingelheim’s director of oncology Albert van Eijk on the digital elements of its multichannel efforts

- PMLiVE

NICE backs Boehringer’s blood clot treatment Pradaxa

Draft DVT and PE guidance puts it on course to catch up with Bayer's Xarelto

- PMLiVE

Boehringer’s Ofev approved by FDA for rare lung disease

US regulator also gives the green light to Intermune's Esbriet

- PMLiVE

Boehringer Ingelheim launches Sound Challenge app

Looks to raise awareness of rare lung disease IPF

- PMLiVE

Liberation strengthens team with new member

Edward Mullin has been appointed as account coordinator

- PMLiVE

Boehringer/Lilly’s Jardiance approved in US

But the FDA wants four post-marketing studies of the SGLT-2 diabetes drug

- PMLiVE

Communiqué recognises emerging health comms talent

Just:: Health's Jon Spiers is Emerging Leader and MHP's Ben Nunn is Rising Star

Boehringer continues award-winning ChatAFib tweet chat

Its next social media discussion follows the programme's Communiqué win

- PMLiVE

Honour for mental health campaigner Marjorie Wallace

SANE founder receives healthcare advocate prize at Communiqué Awards 2014

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links